Wegovy Users Maintain Weight Loss for 4 Years: Here's How It Works

Updated Dec 3, 2024 | 09:00 PM IST

SummaryWegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. People receiving weight-loss drug Wegrovy sustained weight loss for up to four years
wegovy

wegovy (Credit: Canva)

People receiving weight-loss drug Wegovy sustained weight loss for up to four years, shedding an average of 10% of their body weight in that time, as per a new study. Wegrovy is a brand that markets semaglutide injections, that have gained widespread attention for their weight-loss effects. The study also found that Semaglutide injections boost an individual's heart health, even when weight loss doesn't take place.

The study, called SELECT, was published in journal Nature Medicine. "At four years, we see ongoing benefits of semaglutide," said Cheng-Han Chen, MD, interventional cardiologist from Cardiologist, who was not involved in the research. Besides the weight loss, it also lead to a loss in cardiovascular outcomes.

The research was conducted on 17000 adults, who had obesity but did not have diabetes. Overall, people who received once-weekly injections of semaglutide lost on average 10.2% of their body weight over the course of four years. All of the study participants continued to lose weight for about 65 weeks, a year and three months, and then their weight remained at a stable level.

Were There Any Side Effects?

However, people's experience with the medication varied. Researchers found no unexpected safety issues with drug during trial. In fact, most the people who withdrew from the study were those who experienced the known symptsoms of the semaglutide injections like nausea, indigestion etc. This occurred mainly during the beginning of the study, as the dose of the medicine is increased to a maximally tolerated dose.

What Did The Results Say?

Of the people on the highest dose of Wegovy, 68% lost at least 5% of their body weight. This compared to 21% of people on the placebo. Additionally, of the total people on Wegovy about 23% lost at least 15% of their body weight. For those in the placebo group, only 1.7% lost that much body weight.

Semaglutide Shows Heart Benefits Beyond Weight Loss

Researchers found that even individuals who did not experience significant weight reduction while on the drug saw a reduced risk of major heart events. Recent analysis of the SELECT trial data revealed that semaglutide significantly lowers the risk of heart attack, stroke, and cardiovascular-related deaths in adults with obesity or those who are overweight. Notably, the results of this study lead the US FDA to approve Novo Nordisk's Wegovy for reducing heart-related risks in this group.

What Is Semaglutide?

Semglutide is the synthetic version of GLP-1—a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called Post nutrition hormones, and help you absorb the energy you just consumed. GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. Ozempic imitates this hormone, thereby, silencing the food chatter in the brain. Interestingly, for some people this food chatter is really quiet ( people with low appetite) and for others it is an outburst, (people who generally binge eat.) So with Ozempic, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.

Are Their Any Side Effects Of Semaglutide?

Semaglutide, marketed under the brand name Wegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. It is also an anti-obesity drug used for long-term weight management. While it can be taken as a subcutaneous injection or orally, it has significant side effects. It primarily impacts your gastrointestinal tract and its side effects include constipation, nausea, abdominal pain, diarrhoea, and fatigue amongst others.

End of Article

Changing Color Of Light Could Help Treat Mental Illness

Updated Mar 16, 2026 | 08:54 AM IST

SummaryA Norwegian psychiatric ward study found that blue-depleted lighting in the evening improved recovery in patients with psychosis and depression. The circadian-adapted design reduced aggression and may help reset body clocks in other settings.
Changing Color Of Light Could Help Treat Mental Illness

Credits: Trondheim Sleep Group/St Olav's hospital

Lights will guide you home, but will it treat your mental illness? It could. According to new findings, changing the color of light could help treat mental illness. A psychiatric unit in Trondheim, Norway is testing how light could be used as a potential treatment for mental health conditions like psychosis and depression. The approach is simple, yet innovative that aims on changing the ward's design to help patients in their recovery. As night falls, filters are lowered over windows and lights are changed. This creates a soothing ambiance and eliminates the blue wavelengths that could disrupt body's internal clock.

The findings have been published in PLOS Medicine, that looked on the patients who were treated in the circadian-adapted ward. The study showed that these patients showed greater clinical improvement and less aggressive behavior. "Just by changing the light spectrum, we can improve the quality of treatment," said Havard Kallestad, a researcher at St Olavs hospital who led the study.

Has This Approach Been Used In Other Areas Of Healthcare?

Researchers are now looking at its use for other healthcare areas, which means beyond the psychiatric wards. The UK's National Institute of Health and Care Research (NIHR) has also called for trials to see if this could "reset" the internal clocks of people who are living in care homes to reduce their behavioral disturbances, especially in dementia patients.

Professor Anthony Gordon of the NIHR said that it was about determining if light therapy could be used to reduce anxiety and improve sleep.

Read: Doctor Explains How Sleep Debt Is Becoming A Crisis In Urban Professionals

How Was The Study Conducted?

The psychiatric unit was divided in two identical halves with the same layout, staffing, and facilities. The key difference between the two was the evening light environment. One of the wards used blue-depleted lighting from 6pm onwards, where blinds and filters blocked similar light from windows and screens.

Whereas the other ward used standard hospital lighting and the unique design allowed researchers to study the impact of different lighting on patient recovery.

What Is Circadian Rhythm And How It Impacts Health?

Circadian rhythm is the body's internal 24-hour clock that regulated the sleep-wake cycle, hormones, digestion, and temperature, which aligns them with day and light. It is primarily controlled by light-sensitive brain cells, or what people commonly call the 'body clock'.

Disruption in the cycle could link to various health issues, which includes mental health problems like depression and cardiovascular diseases. This is why the test in Trondheim could prove beneficial in treating patients across the spectrum of illness.

End of Article

Fish Oil Supplements Cut Heart Attacks And Strokes Risk In Dialysis Patients

Updated Mar 15, 2026 | 05:55 PM IST

SummaryParticipants who took four grams of fish oil each day experienced a 43 percent reduced risk of major cardiovascular events, including heart attack, stroke, cardiac death and vascular-related amputations than those who received a placebo
Fish Oil Supplements Cut Heart Attacks And Strokes Risk In Dialysis Patients

Credit: Canva

Dialysis patients who took daily fish oil supplements had a 43 percent lower risk of major cardiovascular events, according to a large international clinical trial jointly led in Australia by Monash Health and the School of Clinical Sciences at Monash University.

Published in The New England Journal of Medicine, the study found that participants who took four grams of fish oil each day experienced significantly fewer major cardiovascular events, including heart attack, stroke, cardiac death and vascular-related amputations than those who received a placebo.

The supplement contained the omega-3 fatty acids EPA and DHA, which are naturally found in fish oil.

Adjunct Professor Kevan Polkinghorne, a nephrologist at Monash Health and adjunct in the School of Clinical Sciences, led the Australian portion of the trial said: "Patients on dialysis have extremely high cardiovascular risk, and very few therapies have been shown to reduce that risk," Professor Polkinghorne said. "In a field where many trials have been negative, this is a significant finding.

"Dialysis patients typically have much lower levels of EPA and DHA than the general population. This may help explain the magnitude of benefit observed in this group."

He also noted that results applied specifically to people undergoing haemodialysis for kidney failure and the findings should not be generalized to healthy individuals or to other groups of patients.

What Are Fish Oil Omega-3s?

Omega-3 fatty acids are polyunsaturated fats known for their crucial role in brain function and overall mental health. Fish oil is particularly rich in EPA and DHA, which are vital components of cell membranes and have strong anti-inflammatory effects in the body.

These omega-3s play a critical role in human development, and they are primarily found in fatty fish and fish oil. Since many people do not consume enough fish, supplementation is often recommended to ensure adequate intake of these essential fatty acids.

Although the body can convert another type of omega-3, alpha-linolenic acid (ALA), into EPA and DHA, this process is not highly efficient. As a result, fish oil supplements may provide a convenient way to ensure optimal levels of omega-3s.

Some popular sources of Omega-3 include:

  • Salmon
  • Cod Liver Oil
  • Algae Oil
  • Oysters
  • Nuts and seeds, such as flaxseeds, chia seeds, and walnuts
  • Plant oils, such as flaxseed oil, soybean oil, and canola oil
  • Fortified foods, such as eggs, yogurt, juices, milk, etc.

Budget 2026: Cheaper Fish In India

Earlier this month, Finance Minister Nirmala Sitharaman announced a surprising tax reduction for India's fishers and marine industry, and experts say it is good news for you too.

Until now, fish caught by Indian vessels beyond territorial waters and brought back to the country for mass consumption has been treated as import, attracting customs duties and integrated goods and services tax (GST).

The combined tax burden raises costs and compliance issues, which discouraged people from deep-sea and exclusive economic zone (EEZ) fishing as well as

However, during her Union Budget 2026 presentation, Sitharaman proposed that fish caught in the EEZ and high seas by Indian fishing vessels are treated as duty-free when brought into Indian ports and treated as exports when landed at foreign ports.

This means that the market availability for Omega-3 packed fishes including salmon, mackerel, tuna, herring and sardines will significantly increase as their existing steep prices see a tremendous fall.

End of Article

This Key Protein Could Revolutionize Malaria Vaccines, Scientists Say

Updated Mar 15, 2026 | 04:34 PM IST

SummaryA group of University of Nottingham researchers have now found a key protein that is an enticing target for new antimalarial interventions.
This Key Protein Could Revolutionize Malaria Vaccines, Scientists Say

Credit: Canva

Malaria infected an estimated 282 million people and caused about 6,10,000 deaths worldwide in 2024, according to the World Health Organization’s (WHO) latest World Malaria Report. The report placed strong emphasis on drug resistance, warning that it remains one of the biggest threats to global elimination goals.

WHO-recommended vaccines helped prevent roughly 170 million cases and one million deaths last year, which is about nine million more than the year before. Around 95 per cent of malaria deaths occurred in the African Region, with children under five forming the largest share.

Within the WHO South-East Asia Region, India represented 73.3 per cent of all malaria cases and 88.7 per cent of all malaria-related deaths. The report also underscored that the world is nowhere close to meeting the targets set under the Global Technical Strategy for malaria 2016–2030.

However, a group of University of Nottingham researchers have now found a key protein that is an enticing target for new antimalarial interventions. The study looked at a protein called Aurora-related kinase 1 (ARK1), which plays an important role in the parasite’s unusual cell division.

ARK1 helps control the parasite’s mitosis (cell division) and organizes a structure called the spindle, which separates genetic material so new parasites can form.

Scientists turned off the ARK1 gene using genetic engineering techniques to see what would happen. Without ARK1, the parasites could not form proper spindles and failed to reproduce, suggesting the protein could be a weak spot that future malaria treatment.

"What makes this discovery so exciting is that the malaria parasite's 'Aurora' complex is very different from the version found in human cells," senior author Rita Tewari said.

What Are Anopheles Stephensi Mosquitoes?

Anopheles stephensi is a malaria-transmitting mosquito originally found in South Asia. Unlike many other malaria vectors, it thrives in cities and breeds in man-made water sources such as storage tanks, containers, and discarded tyres. It can carry both Plasmodium falciparum and P. vivax parasites.

In recent years, this mosquito has spread into several African countries, where it adapts easily and shows resistance to multiple insecticides. This expansion has increased the threat of urban malaria outbreaks, as highlighted by the World Health Organization.

At present, Anopheles stephensi has been detected in nine African countries and is proving difficult to control due to widespread insecticide resistance.

Malaria Vaccines

The report noted that WHO approved the world’s first malaria vaccines in 2021, and 24 countries have now added them to their regular immunisation schedules. Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said that new preventive tools provide reason for optimism, but many obstacles remain.

He pointed out the rise in cases and deaths, the pressure from drug resistance, and the impact of reduced funding. These factors could undermine the progress achieved over the last twenty years.

End of Article